NCIt definition : A recombinant humanized bispecific antibody directed against the negative immunoregulatory
human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human
vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory,
anti-angiogenic and antineoplastic activities. Upon administration, anti-PD-1/anti-VEGF
bispecific antibody JS207 simultaneously targets and binds to both PD-1 expressed
on T-cells and VEGF expressed on tumor cells. The binding of JS207 to PD-1 prevents
the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1; CD274)
and/or 2 (PD-L2; CD273). This abrogates T-cell inhibition, activates antigen-specific
T-lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis,
which may lead to a reduction in tumor growth. The binding of JS207 to VEGF prevents
binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and
may lead to the inhibition of vascular endothelial cell proliferation. The inhibition
of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis.
PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on
T-cells, functions as an immune checkpoint that negatively regulates T-cell activation
and effector function when activated by its ligands PD-L1 and/or PD-L2; it plays an
important role in tumor evasion from host immunity. VEGF is overexpressed in a variety
of cancers and is associated with increased invasiveness and decreased survival.;
Semantic type(s)